Clinical Trials | May 20, 2022
Motilal Oswal Private Equity (MOPE) invests in Pathkind Diagnostics
A primary investment of Rs 194.4 crore has been made
A primary investment of Rs 194.4 crore has been made
Purpose-built bioconjugation facility in Lonza’s Ibex Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseases
With the approval from the Central Drugs Standard Control Organisation (CDSCO), Jardiance is now the first approved therapy to improve outcomes for the full spectrum of heart failure regardless of ejection fraction
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
The centres will be located in Tier I and Tier II cities
Bempedoic Acid administered as a 180-mg dose, is approved by the USFDA and European Union for the treatment of hypercholesterolemia
Wearable patch sensors (smart patches) are rising in popularity, as they offer a wide range of options for medical diagnosis
A total of three targets have been selected for portfolio entry in the collaboration to date, with the potential to generate further future development milestones and sales-based royalty revenues for BenevolentAI
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
Subscribe To Our Newsletter & Stay Updated
